NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
NOVARTIS AG-SPONSORED ADR
NYSE:NVS (11/21/2024, 7:00:00 PM)
After market: 103 -0.85 (-0.82%)103.85
+0.76 (+0.74%)
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 76,057 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056
P: 41613241111
CEO: Vasant (Vas) Narasimhan
Employees: 76057
Website: https://www.novartis.com/
NVS News
18 hours ago - BloombergNovartis Raises Sales Guidance Citing Cancer, Inflammatory DrugsNovartis AG raised its medium-term sales guidance, citing upbeat expectations for new cancer and immunological disease medicines, as well as treatments for neurological and cardiovascular conditions.
2 days ago - CNBCHealthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trialEli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
3 days ago - The Business JournalsNovartis signs deal with Mass. company worth up to $745M3 days ago - Ratio Therapeutics Inc.Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate/PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for...
6 days ago - Zacks Investment ResearchHere's Why Novartis (NVS) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
7 days ago - Market News VideoJuly 2025 Options Now Available For Novartis (NVS)NVS Twits
Here you can normally see the latest stock twits on NVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
